Timeline
More in Markets
Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer
Positive overall survival data from a China trial of risvutatug rezetecan marks the first Phase III success for any B7-H3-targeted antibody-drug conjugate, strengthening GSK's broader development programme.